CRDL
NASDAQ
$1.03
Cardiol Therapeutics Inc - Class A (CRDL)
Cardiol Therapeutics Inc., a clinical-phase biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular diseases (CVD). The company is headquartered in Oakville, Canada.
Sector:
Healthcare
Strong Buy
Target: $7.22 (+600.97%)
Market Cap
$114M
Free Cash Flow Yield
-15.37%
Beta (5Y)
1.32
Price Chart
Valuation
Market Cap$114M
P/S1014.87
P/B6.97
Profitability
Gross Profit (TTM)$57K
EBITDA-$25M
EPS-$0.28
Financial Health
Debt-to-Equity0.5%
Free Cash Flow Yield-15.37%
Growth & Risk
EPS 5Y CAGR-10.43%
FCF 5Y CAGR+10.21%
Beta (5Y)1.32
Sharpe Ratio-0.15